Drug Profile
Savolitinib - AstraZeneca/HUTCHMED
Alternative Names: AZD-6094; HMP-504; HMPL-504; Orpathys; Volitinib; VoressaLatest Information Update: 10 Apr 2024
Price :
$50
*
At a glance
- Originator Hutchison MediPharma
- Developer AstraZeneca; Hutchison MediPharma; HUTCHMED; National Cancer Institute (USA); Samsung Medical Center
- Class Antineoplastics; Imidazoles; Pyrazines; Pyrazoles; Pyridines; Small molecules; Triazoles
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase III Renal cell carcinoma
- Phase II Colorectal cancer; Gastric cancer; Oesophageal cancer; Prostate cancer
- No development reported CNS cancer; Solid tumours
Most Recent Events
- 10 Apr 2024 AstraZeneca plans a phase I trial in Healthy volunteers (In adults) in Sweden (PO) in April 2024 (NCT06348355) (EudraCT2023-508334-34-00)
- 28 Mar 2024 National Medical Products Administration (NMPA) accepts the supplemental New Drug Application for savolitinib for Non-small cell lung cancer for review
- 28 Mar 2024 Updated efficacy and adverse events data from a phase IIIb trial in Non small cell lung cancer released by HUTCHMED